Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

Ybx2 Gene Function From Germ Cell Formation To Adipose Tissue Regulation

Cyagen Technical Content Team | August 29, 2025
Explore Ybx2 Knockout Mice from Cyagen
Ybx2 Knockout: A Key Regulator of Germ Cell Development and Brown Adipogenesis
Explore Ybx2 Knockout Mice from Cyagen
Contents
01. Ybx2 Knockout Mice: Disruption of Germ-Cell Development and Infertility in Both Sexes 02. Phenotype: Arrested Spermiogenesis and Accelerated Oocyte Loss Leading to Infertility 03. New Research Progress: Ybx2 as a Key Regulator of Brown Adipocyte Differentiation 04. Summary: Ybx2 as a Critical Factor in Germ Cell Formation and mRNA Stability

In the previous article, we described how the regulatory mechanism of the YBX2 gene influences development of cancer. In mouse models, what did the researchers find? How does Ybx2 knockout affect mouse phenotype? Please find the answers below, in our Weekly Model research review.

Ybx2 Knockout Mice: Disruption of Germ-Cell Development and Infertility in Both Sexes

Firstly, Juxiang Yang et al. constructed Ybx2 knockout mouse; they found that Ybx2 represents one of a small number of germ-cell-specific genes whose deletion leads to the disruption of both spermatogenesis and oogenesis.

Targeting Construct and Generation of Mice

The Ybx2 –/– targeting construct (Fig. 1A) was produced by using a 129S6/SvEv mouse genomic library that is isogenic with the AB2.2 ES cells used for electroporation. ES cell clones were electroporated, selected, and screened by Southern blotting. As shown in Figure 1A, eight of 87 (9.2%) ES cell clones analyzed were correctly targeted on both the 5′ and 3′ sides by using the noted probes. Germ-line transmission was achieved from ES cell clone Ybx2-188-A6. Mice were genotyped by Southern blotting, and the mutation was maintained on a 129S5/SvEvBrd hybrid genetic background.

Strategy for targeted disruption of the Ybx2 gene [1]
Figure 1. Strategy for targeted disruption of the Ybx2 gene [1]

Phenotype: Arrested Spermiogenesis and Accelerated Oocyte Loss Leading to Infertility

Spermatogenesis Arrests in Late Spermiogenesis in Ybx2 –/– Males

To determine the cause of the infertility in the Ybx2 –/– males, testes were initially analyzed at 6 weeks of age. Testes of the Ybx2 –/– males (63.95 ± 3.52 mg; n = 6) were statistically smaller (P < 0.001) than testes of the wild-type males (88.68 ± 3.77 mg; n = 6). The absence of Ybx2 results in a block late in spermatogenesis, likely secondary to the altered regulation of key spermatogenic genes that are expressed after the meiotic division.

Histology of testes and epididymis from 6- and 7-week-old wild-type and Ybx2-null (knockout) mice. (A and B) Ybx2 –/– testis. (C) Ybx2 +/+ testis. (D) Ybx2 –/– testis. (E) Ybx2 +/+ epididymis. (F) Ybx2 –/– epididymis. (Scale bars: A, E, and F, 20 μm; B–D, 80 μm.)
Figure 2. Histology of testes and epididymis from 6- and 7-week-old wild-type and Ybx2-null (knockout) mice. (A and B) Ybx2 –/– testis. (C) Ybx2 +/+ testis. (D) Ybx2 –/– testis. (E) Ybx2 +/+ epididymis. (F) Ybx2 –/– epididymis. (Scale bars: A, E, and F, 20 μm; B–D, 80 μm.)

An Early Loss of Oocytes Occurs in Ybx2 –/– Females

The researchers analyzed the ovaries at various time points to study infertility in Ybx2-/- females. By 21 days of age, they found there were fewer follicles in the Ybx2 –/– female ovaries (Fig. 5C ), and in many of those present, the granulosa cells appeared to be disorganized. This finding is in contrast to the age-matched littermate control ovaries that had multiple secondary and earlier follicles (Fig. 5 A and B). By 8 weeks of age, wild-type ovaries had a full range of follicles and corpora lutea (Fig. 5D), whereas Ybx2 –/– ovaries had fewer follicles and occasional hemorrhagic cysts (Fig. 5E). By 20 weeks, there was a range of phenotypes in the Ybx2 –/– ovaries that likely depended on the number of oocytes lost earlier in life: some ovaries had cysts, oocytes lacking cumulus cells (Fig. 5F), and significant oocyte death that included an interstitium full of zona pellucida remnants and zonae pellucidae being “invaded” by granulosa cells (Fig. 5G). Other ovaries had mostly preantral follicles, with an occasional follicle containing two oocytes and oocytes that appeared larger than normal (data not shown). By 8 months of age, Ybx2 –/– ovaries continued to vary in size and follicle number. Three of nine Ybx2 –/– mice had ovaries that were small and typically devoid of oocytes and follicles (Fig. 5 H and I).

Histology of ovaries of Ybx2-null and control mice. (A–C) Three-week-old wild-type (A), Ybx2 +/– (B), and Ybx2 –/– (C) ovaries captured at the same magnification. (D) Wild-type 8-week-old ovary. (E–I) Ybx2 –/– ovaries at 8 weeks (E), 20 weeks (F and G), and 8 months (H and I). Note the numerous follicles in A and B compared with C. Note the numerous corpora lutea (CL) and follicles at various stages of development in D and the absence of corpora lutea, reduced number of follicles, hemorrhagic cyst (HC), and increased interstitial tissue in E. (Scale bars: 100 μm.)
Figure 4. Histology of ovaries of Ybx2-null and control mice. (A–C) Three-week-old wild-type (A), Ybx2 +/– (B), and Ybx2 –/– (C) ovaries captured at the same magnification. (D) Wild-type 8-week-old ovary. (E–I) Ybx2 –/– ovaries at 8 weeks (E), 20 weeks (F and G), and 8 months (H and I). Note the numerous follicles in A and B compared with C. Note the numerous corpora lutea (CL) and follicles at various stages of development in D and the absence of corpora lutea, reduced number of follicles, hemorrhagic cyst (HC), and increased interstitial tissue in E. (Scale bars: 100 μm.)

New Research Progress: Ybx2 as a Key Regulator of Brown Adipocyte Differentiation

Recent years have seen an upsurge of interest in brown adipose tissue (BAT) to combat the epidemic of obesity and diabetes. Dan Xu et. al. found Ybx2 is a novel regulator that controls BAT activation by regulating mRNA stability.

Ybx2 Is an Essential Regulator of Brown Adipocyte Differentiation In Vitro

Ybx2 is an essential regulator of brown adipocyte differentiation in vitro. A: Primary brown preadipocytes were infected by retroviral shRNAs targeting RBPs, Ybx2, and Akap1, followed by induction of differentiation for 5 days. Oil Red O staining was used to assess lipid accumulation. B–D: Real-time PCR was used to measure the knockdown efficiency (left), pan-adipogenic marker expression (right), and BAT-selective marker expression (bottom) in cultured primary brown adipocytes (day 5) infected by retroviral shRNAs targeting Ybx2 (B), Akap1 (C), and Rbpms2 (D) (n = 3). *P , 0.05 by one-way ANOVA. F: Representative metabolic flux curves from cultured brown adipocytes (day 5) infected by retroviral shRNA targeting Ybx2. Cells were sequentially treated with oligomycin, FCCP, and rotenone. OCRs are normalized by protein concentration (n = 5). *P , 0.05 by Student t test. F: Western blot was used to examine the protein levels of Ybx2 during primary brown and white adipocyte differentiation in culture. The error bars in the graphs are mean 6 SEM. Sh-1, short hairpin RNA-1; Sh-2, short hairpin RNA-2; Sh-3, short hairpin RNA-3. [2]

Figure 5. Ybx2 is an essential regulator of brown adipocyte differentiation in vitro. A: Primary brown preadipocytes were infected by retroviral shRNAs targeting RBPs, Ybx2, and Akap1, followed by induction of differentiation for 5 days. Oil Red O staining was used to assess lipid accumulation. B–D: Real-time PCR was used to measure the knockdown efficiency (left), pan-adipogenic marker expression (right), and BAT-selective marker expression (bottom) in cultured primary brown adipocytes (day 5) infected by retroviral shRNAs targeting Ybx2 (B), Akap1 (C), and Rbpms2 (D) (n = 3). *P , 0.05 by one-way ANOVA. F: Representative metabolic flux curves from cultured brown adipocytes (day 5) infected by retroviral shRNA targeting Ybx2. Cells were sequentially treated with oligomycin, FCCP, and rotenone. OCRs are normalized by protein concentration (n = 5). *P , 0.05 by Student t test. F: Western blot was used to examine the protein levels of Ybx2 during primary brown and white adipocyte differentiation in culture. The error bars in the graphs are mean 6 SEM. Sh-1, short hairpin RNA-1; Sh-2, short hairpin RNA-2; Sh-3, short hairpin RNA-3. [2]

These observations indicate that Ybx2 can promote brown adipogenesis in white adipocyte culture and also accelerate brown adipogenesis in brown adipocyte culture. Additional in vivo research, such as involving the use of mouse models, would provide further evidence of the mechanism of action (MOA) of Ybx2 in brown adipogenesis to evaluate potential therapeutic approaches.

Summary: Ybx2 as a Critical Factor in Germ Cell Formation and mRNA Stability

The YBX2 gene is a germ cell-specific gene, and the phenotype of knockout mice is mainly focused on germ cells. These results indicate that suitable knockout mice are helping to study how the formation of germ cells are influenced by Ybx2. In addition, the Ybx2 gene has a lot to do with the stability of mRNA. Researchers can refer to the results of Ybx2 in vitro experiments to see whether the gene will produce a similar phenomenon in mice and whether there is a compensatory pathway.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
Beyond Subretinal Injections: How AI is Reshaping AAV Capsid Engineering for Retinal Gene Therapy
Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics
Mastering AAV Cardiac Delivery: Serotypes, Promoters, and Ready-to-Use Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research